Finerenone for children with heart failure
Treatments studied
Part of Heart & circulation clinical trials.
This study tests a new medicine called finerenone (a pill) to see if it helps children with heart failure who have a weak pumping heart. It compares finerenone to a placebo (a pill with no medicine) while both groups continue their usual heart treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 months and 18 years old.
- Your child must have heart failure with a weak pumping heart (ejection fraction 50% or less).
- Your child must have a blood test showing high NT-proBNP levels (a sign of heart strain).
- Your child must be on stable heart failure medications for at least 30 days.
- Your child must weigh at least 4 kilograms (about 8.8 pounds).
- Your child cannot have taken spironolactone or eplerenone in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the long-term safety of the drug finerenone when taken alongside standard heart failure treatments in children and young adults with weakened heart pumping function (left ventricular systolic dysfunction). It includes both children already in a related study and new infants under 6 months old.
This study tests whether a medication called finerenone can reduce scarring in the heart and improve heart function in people with heart failure who have ejection fractions of 40% or higher. You may be eligible if you've recently had heart failure symptoms requiring emergency care or medication changes.
This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.
This trial studies how safely finerenone works over 18 months in children and young adults with chronic kidney disease who also take an ACE inhibitor or ARB. It aims to better understand long-term side effects when used together with standard kidney blood-pressure medicines.
This study tests whether finerenone, a new type of drug, can help people with heart failure who cannot take standard steroid-based MRAs (a kind of heart medication) because of side effects or other reasons. It aims to see if it improves symptoms and is safe for you.
This trial tests how safe and effective finerenone is for adults with chronic heart failure. It includes people whose heart pumps blood with at least 40% efficiency.
Hear when a new Left Ventricular Systolic Dysfunction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.